Research analysts at StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Stock Down 2.5 %
Agile Therapeutics stock opened at $0.24 on Friday. The company has a market capitalization of $9.54 million, a P/E ratio of -0.02 and a beta of 1.13. The firm has a 50 day moving average price of $0.26 and a 200-day moving average price of $0.28. Agile Therapeutics has a twelve month low of $0.18 and a twelve month high of $12.38.
Hedge Funds Weigh In On Agile Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Agile Therapeutics during the 4th quarter valued at about $32,000. BlackRock Inc. lifted its holdings in Agile Therapeutics by 538.6% during the third quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock valued at $91,000 after purchasing an additional 256,227 shares in the last quarter. Jane Street Group LLC purchased a new position in Agile Therapeutics during the second quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Agile Therapeutics by 281.3% in the first quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 458,300 shares in the last quarter. Institutional investors own 5.70% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
- Get a free copy of the StockNews.com research report on Agile Therapeutics (AGRX)
- Hormel Hits 2-Year Low, And The Dip Gets Bought
- Here’s Why Ross Could Soon Be Hitting All Time Highs
- The Bottom Is In For Salesforce.com
- It’s Time For A Fresh Look At The Kroger Co.
- West Fraser’s Earnings Scream Timber, Outlook Says Buy
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.